Royal Bank Of Canada Cuts Aveanna Healthcare (NASDAQ:AVAH) Price Target to $9.00

Aveanna Healthcare (NASDAQ:AVAH) had its target price trimmed by Royal Bank Of Canada from $11.00 to $9.00 in a research note released on Monday,Benzinga reports. The firm currently has a sector perform rating on the stock.

Several other research firms also recently issued reports on AVAH. UBS Group lifted their price target on shares of Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “neutral” rating in a research note on Thursday, January 15th. Truist Financial decreased their price objective on shares of Aveanna Healthcare from $10.00 to $9.00 and set a “hold” rating for the company in a research report on Friday, March 20th. William Blair initiated coverage on Aveanna Healthcare in a research report on Monday, December 8th. They set an “outperform” rating on the stock. Weiss Ratings upgraded Aveanna Healthcare from a “hold (c)” rating to a “buy (b-)” rating in a research note on Friday, March 20th. Finally, Barclays increased their price target on Aveanna Healthcare from $9.00 to $11.00 and gave the company an “overweight” rating in a report on Friday, January 16th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $10.38.

Aveanna Healthcare Trading Up 0.2%

AVAH opened at $6.62 on Monday. The firm’s 50 day moving average is $7.71 and its 200-day moving average is $8.46. Aveanna Healthcare has a 52-week low of $3.73 and a 52-week high of $10.32. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 6.62. The firm has a market capitalization of $1.44 billion, a P/E ratio of 6.49 and a beta of 2.07.

Insider Activity

In other news, CEO Jeff Shaner sold 173,225 shares of Aveanna Healthcare stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $7.21, for a total value of $1,248,952.25. Following the completion of the transaction, the chief executive officer directly owned 2,650,892 shares of the company’s stock, valued at approximately $19,112,931.32. The trade was a 6.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Patrick A. Cunningham sold 18,436 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $7.21, for a total transaction of $132,923.56. Following the sale, the insider directly owned 337,755 shares of the company’s stock, valued at approximately $2,435,213.55. This represents a 5.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 998,595 shares of company stock valued at $7,567,770 over the last quarter. 7.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Aveanna Healthcare

A number of large investors have recently bought and sold shares of AVAH. Caitong International Asset Management Co. Ltd boosted its stake in Aveanna Healthcare by 252.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,351 shares of the company’s stock valued at $27,000 after acquiring an additional 2,400 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Aveanna Healthcare during the 2nd quarter worth approximately $43,000. Oxford Asset Management LLP bought a new stake in shares of Aveanna Healthcare in the 2nd quarter worth approximately $64,000. Dynamic Technology Lab Private Ltd acquired a new position in Aveanna Healthcare during the 2nd quarter valued at approximately $68,000. Finally, PharVision Advisers LLC acquired a new position in Aveanna Healthcare during the 2nd quarter valued at approximately $78,000. Institutional investors own 87.96% of the company’s stock.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.